Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pediatric omaveloxolone study in Friedreich's ataxia
NL-OMON59415Phase 3Recruiting
- Sponsor
- Biogen
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omaveloxolone in Friedreich ataxia (FA) (3 arms), sponsored by Biogen. Primary endpoints: Change from baseline in upright stability score and Incidence of adverse events and serious adverse events. Started Oct 2025; status: recruiting.
02
Drugs
omaveloxolone
03
Conditions
Friedreich ataxia (FA)
Beyond the preview
Go deeper on NL-OMON59415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59415.